| 0.7829 -0.071 (-8.34%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.25 |
1-year : | 1.53 |
| Resists | First : | 1.07 |
Second : | 1.3 |
| Pivot price | 1.09 |
|||
| Supports | First : | 0.7 |
Second : | 0.58 |
| MAs | MA(5) : | 0.99 |
MA(20) : | 1.1 |
| MA(100) : | 1.16 |
MA(250) : | 1.62 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 15.3 |
| RSI | RSI(14): 31.9 |
|||
| 52-week | High : | 3.35 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HUMA ] has closed below the lower bollinger band by 17.0%. Bollinger Bands are 50.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.92 | 0.92 - 0.92 |
| Low: | 0.69 - 0.7 | 0.7 - 0.7 |
| Close: | 0.76 - 0.77 | 0.77 - 0.78 |
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Fri, 20 Mar 2026
Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess - Yahoo Finance
Thu, 19 Mar 2026
Humacyte Announces $20 Million Registered Direct Offering - TipRanks
Thu, 19 Mar 2026
Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today? - Stocktwits
Thu, 19 Mar 2026
Humacyte stock price target maintained at $6 by BTIG on Saudi deal - Investing.com
Thu, 19 Mar 2026
Saudi hospitals to evaluate Humacyte vessel under $1.475M deal - Stock Titan
Thu, 19 Mar 2026
Humacyte raises $20M to back Symvess launch and Phase 3 readout - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 193 (M) |
| Held by Insiders | 1.5704e+008 (%) |
| Held by Institutions | 16.3 (%) |
| Shares Short | 37,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.732e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 239 % |
| Return on Equity (ttm) | -63.5 % |
| Qtrly Rev. Growth | 1.57e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.82383e+007 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -49.54 |
| Dividend | 0 |
| Forward Dividend | 3.919e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|